AWH Capital L.P. Takes $866,000 Position in Liquidia Corporation $LQDA

AWH Capital L.P. bought a new position in shares of Liquidia Corporation (NASDAQ:LQDA) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 69,500 shares of the company’s stock, valued at approximately $866,000. Liquidia comprises 1.0% of AWH Capital L.P.’s portfolio, making the stock its 19th biggest position. AWH Capital L.P. owned about 0.08% of Liquidia at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of LQDA. Bluefin Capital Management LLC bought a new position in shares of Liquidia during the 1st quarter valued at about $250,000. XTX Topco Ltd bought a new stake in shares of Liquidia in the second quarter worth about $1,485,000. Diametric Capital LP lifted its position in shares of Liquidia by 72.5% in the second quarter. Diametric Capital LP now owns 148,601 shares of the company’s stock worth $1,852,000 after buying an additional 62,443 shares in the last quarter. Tyro Capital Management LLC bought a new position in Liquidia during the second quarter valued at approximately $15,473,000. Finally, Y Intercept Hong Kong Ltd purchased a new position in Liquidia during the 2nd quarter valued at approximately $775,000. 64.54% of the stock is owned by hedge funds and other institutional investors.

Liquidia Stock Up 2.4%

NASDAQ LQDA opened at $33.38 on Friday. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. Liquidia Corporation has a 52 week low of $10.37 and a 52 week high of $35.54. The firm has a market capitalization of $2.90 billion, a price-to-earnings ratio of -23.18 and a beta of 0.48. The company has a fifty day moving average of $27.41 and a two-hundred day moving average of $22.46.

Liquidia (NASDAQ:LQDA) last released its earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $54.34 million during the quarter, compared to analyst estimates of $18.86 million. The company’s revenue for the quarter was up 1106.7% compared to the same quarter last year. On average, analysts predict that Liquidia Corporation will post -1.51 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO Michael Kaseta sold 1,166 shares of the business’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $32.19, for a total transaction of $37,533.54. Following the completion of the transaction, the chief financial officer owned 353,823 shares in the company, valued at $11,389,562.37. The trade was a 0.33% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev Saggar sold 71,381 shares of the business’s stock in a transaction on Wednesday, November 5th. The shares were sold at an average price of $27.00, for a total value of $1,927,287.00. Following the transaction, the insider owned 176,549 shares of the company’s stock, valued at approximately $4,766,823. The trade was a 28.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 215,168 shares of company stock valued at $5,675,425 over the last quarter. Corporate insiders own 26.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research note on Wednesday, October 8th. Wall Street Zen cut shares of Liquidia from a “buy” rating to a “hold” rating in a research report on Saturday, December 6th. Needham & Company LLC upped their price target on shares of Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. HC Wainwright lifted their price objective on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, BTIG Research restated a “buy” rating and issued a $49.00 target price on shares of Liquidia in a report on Tuesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Liquidia presently has an average rating of “Moderate Buy” and a consensus target price of $38.56.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).